My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

92.14 +0.59 (+0.64%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 23, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

74 75 Next >

Health Care Company AstraZeneca Announces Acquisition of Icosavax ↗

December 12, 2023

Via Benzinga

Oracle's Falling, but You Won't Want to Miss This Soaring Biotech Stock ↗

December 12, 2023

Tuesday brought favorable inflation data, and bullish investors are looking for stock winners.

Via The Motley Fool

Topics Economy

Why Is Icosavax (ICVX) Stock Up 46% Today? ↗

December 12, 2023

Icosavax stock is up on Tuesday as investors react to an acquisition deal with AstraZeneca that values ICVX between $15 and $20 per share.

Via InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

December 12, 2023

Checking out the biggest pre-market stock movers for Tuesday is the perfect way to get ready for another busy day of trading!

Via InvestorPlace

AstraZeneca to Acquire Icosavax, Including Potential First-in-class RSV and hMPV Combination Vaccine With Positive Phase II Data

December 12, 2023

From AstraZeneca

Via Business Wire

Industry Comparison: Evaluating AstraZeneca Against Competitors In Pharmaceuticals Industry ↗

November 27, 2023

Via Benzinga

AstraZeneca To Acquire US Respiratory Vaccine Player Icosavax For Over $800M ↗

December 12, 2023

AstraZeneca Plc (NASDAQ: AZN) has agreed to acquire Icosavax Inc (NASDAQ: ICVX) at $15.00 per share in cash at closing, plus a non-tradable contingent value right to receive up to $5.00 in cash,...

Via Benzinga

Neurology Focused Pasithea Therapeutics Stock Soars Over 150% Today - Here's Why ↗

December 11, 2023

Pasithea Therapeutics Corp (NASDAQ: KTTA) announced preclinical results from two in vivo studies evaluating the antitumor efficacy of PAS-004 in NRAS mutation

Via Benzinga

AstraZeneca's Investigational Drug Shows Durable Clinical Benefit In Patients With Rare Blood Disease ↗

December 11, 2023

AstraZeneca Plc (NASDAQ: AZN)

Via Benzinga

Long-term ALPHA Phase III trial data showed danicopan as add-on to ULTOMIRIS® or SOLIRIS® sustained clinical improvements in subset of patients with PNH experiencing clinically significant extravascular hemolysis

December 10, 2023

From Alexion

Via Business Wire

AstraZeneca Just Joined the AI Drug Development Craze, but Is It a Buy in 2024? ↗

December 10, 2023

It'll take a few years for its latest moves to pay off, assuming they do.

Via The Motley Fool

Topics Artificial Intelligence

Is Now the Right Time to Buy AstraZeneca Stock? ↗

December 10, 2023

The pharmaceutical giant is making strident moves to compete in hot markets, but it's not a cheap stock.

Via The Motley Fool

Pharma Industry on Alert as Biden Administration Explores Patent Seizure Powers ↗

December 07, 2023

The White House is endorsing a contentious power that permits the government to reclaim patents for specific

Via Benzinga

Topics Intellectual Property

AstraZeneca Strikes Deal With Absci To Leverage AI In Cancer Drug Discovery: Report ↗

December 04, 2023

AstraZeneca plc (NASDAQ: AZN) has reportedly finalized a partnership deal valued at up to $247 million with Absci Corporation (NASDAQ: ABSI), a U.S.-based firm specializing in artificial intelligence...

Via Benzinga

Topics Artificial Intelligence

Week In Review: Tang Capital Offers $465 Million For LianBio Plus 80% Of Any Licenses/Divestments ↗

December 02, 2023

LianBio received a $465 million buyout offer from Tang Capital Management. In addition, Tang also offered shareholders a contingent value right for 80% of net proceeds from any license or divestment of...

Via Talk Markets

Weight Loss Drugs And Associated Suicidal Thoughts - European Drug Regulator Seeks Clarifications From Drug Makers ↗

December 01, 2023

European Medicines Agency (EMA) will request further clarifications from drugmakers of GLP-1 receptor agonists for diabetes and weight loss, including Novo Nordisk A/S's (NYSE: NVO) popular therapies...

Via Benzinga

AstraZeneca Stops Two Lokelma Late-Stage Trials After Evaluating Potential Benefits ↗

December 01, 2023

AstraZeneca Plc (NASDAQ: AZN) discontinued the STABILIZE-

Via Benzinga

AstraZeneca advances scientific leadership in hematology at ASH 2023

November 29, 2023

From AstraZeneca

Via Business Wire

Week In Review: BeiGene Signs $1.3 Billion Deal For Preclinical CDK2 Inhibitor From Boston’s Ensem ↗

November 25, 2023

Beijing’s BeiGene acquired global rights to a preclinical novel cyclin-dependent kinase 2 (CDK2) inhibitor from Boston’s Ensem Therapeutics in a $1.3 billion agreement. Ensem will receive an upfront...

Via Talk Markets

Eli Lilly and Novo Nordisk Are Big Names in Weight Loss, but Investors Shouldn't Count Out This Healthcare Giant ↗

November 22, 2023

Could AstraZeneca be an under-rated buy right now?

Via The Motley Fool

3 No-Brainer Stocks to Buy With $1,000 Right Now ↗

November 22, 2023

A modest amount of money can go a long way when it's invested in industry-leading businesses with sustained, long-term catalysts.

Via The Motley Fool

5 Growth Stocks to Buy for 2024 ↗

November 20, 2023

Forget the "Magnificent 7." These are the top five growth stocks to buy in the coming year for interested investors.

Via InvestorPlace

AstraZeneca launches Evinova, a health-tech business to accelerate innovation across the life sciences sector, the delivery of clinical trials and better health outcomes

November 20, 2023

From AstraZeneca

Via Business Wire

3 stocks that crushed earnings estimates and still tanked

November 20, 2023

Every earnings season, regardless of sector or industry, has its share of stocks that go down even after beating earnings expectations such as these stocks

Via MarketBeat

US CDC Rolls Out Additional Doses For Sanofi/AstraZeneca Recently Approved Respiratory Infection Drug As Demand Surges ↗

November 17, 2023

The U.S.

Via Benzinga

AstraZeneca Is Trying to Make an Ozempic Competitor (Again), but Don't Rush to Buy the Stock ↗

November 17, 2023

It might have a hard time finding a home in the market.

Via The Motley Fool

FDA Approves AstraZeneca's Truqap/Faslodex Combo Therapy For Breast Cancer, Competes With Gilead's Drug ↗

November 17, 2023

FDA approves AstraZeneca Plc's (NASDAQ: AZN) Truqap (capivasertib) in combination with Faslodex (fulvestrant) for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative...

Via Benzinga

TRUQAP™ (capivasertib) plus fulvestrant approved in the US for patients with advanced HR-positive breast cancer

November 17, 2023

From AstraZeneca

Via Business Wire

FDA Approves Bristol-Myers' Lung Cancer Drug Acquired Via $4B Turning Point Deal: Competes With Roche, Merck, AstraZeneca ↗

November 16, 2023

The FDA approved Bristol Myers Squibb And Co's (NYSE: BMY) Augtyro (repotrectinib) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small

Via Benzinga

AstraZeneca's Flagship Cancer Drug Imfinzi Fails On Main Goal In Lung Cancer Trial When Combined With Chemoradiotherapy ↗

November 14, 2023

AstraZeneca Plc (NASDAQ: AZN) said its PACIFIC

Via Benzinga

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

74 75 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.